SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law..
Purpose of Review: The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination.
Recent Findings: Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1-20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination.
Summary: Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Current dermatology reports - 11(2022), 4 vom: 24., Seite 252-262 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Himed, Sonia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 cutaneous eruptions |
|---|
| Anmerkungen: |
Date Revised 18.09.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s13671-022-00374-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34789349X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34789349X | ||
| 003 | DE-627 | ||
| 005 | 20231226034919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13671-022-00374-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM34789349X | ||
| 035 | |a (NLM)36274753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Himed, Sonia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review: The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination | ||
| 520 | |a Recent Findings: Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1-20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination | ||
| 520 | |a Summary: Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 cutaneous eruptions | |
| 650 | 4 | |a COVID-19 disease severity | |
| 650 | 4 | |a COVID-19 vaccinations | |
| 650 | 4 | |a COVID-19 vaccine reactions | |
| 700 | 1 | |a Gray, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Awethe, Zaynah |e verfasserin |4 aut | |
| 700 | 1 | |a Libson, Karissa |e verfasserin |4 aut | |
| 700 | 1 | |a Kaffenberger, Benjamin H |e verfasserin |4 aut | |
| 700 | 1 | |a Korman, Abraham M |e verfasserin |4 aut | |
| 700 | 1 | |a Trinidad, John C L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current dermatology reports |d 2012 |g 11(2022), 4 vom: 24., Seite 252-262 |w (DE-627)NLM226627772 |x 2162-4933 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:4 |g day:24 |g pages:252-262 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13671-022-00374-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 4 |b 24 |h 252-262 | ||